119 related articles for article (PubMed ID: 12201961)
1. Factors affecting purification of CD34(+) peripheral blood stem cells using the Baxter Isolex 300i.
Gryn J; Shadduck RK; Lister J; Zeigler ZR; Raymond JM
J Hematother Stem Cell Res; 2002 Aug; 11(4):719-30. PubMed ID: 12201961
[TBL] [Abstract][Full Text] [Related]
2. A controlled comparison of two different clinical grade devices for CD34+ cell selection of autologous blood stem cell grafts.
Björkstrand B; Sundman-Engberg B; Christensson B; Kumlien G
J Hematother; 1999 Feb; 8(1):75-80. PubMed ID: 10192304
[TBL] [Abstract][Full Text] [Related]
3. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
4. Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
Bensinger W; Appelbaum F; Rowley S; Storb R; Sanders J; Lilleby K; Gooley T; Demirer T; Schiffman K; Weaver C
J Clin Oncol; 1995 Oct; 13(10):2547-55. PubMed ID: 7595706
[TBL] [Abstract][Full Text] [Related]
5. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device.
Després D; Flohr T; Uppenkamp M; Baldus M; Hoffmann M; Huber C; Derigs HG
J Hematother Stem Cell Res; 2000 Aug; 9(4):557-64. PubMed ID: 10982256
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
[TBL] [Abstract][Full Text] [Related]
7. Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy.
Prince HM; Bashford J; Wall D; Rischin D; Parker N; Toner GC; Seymour JF; Blakey D; Haylock D; Simmons P; Francis P; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
Cytotherapy; 2002; 4(2):137-45. PubMed ID: 12006209
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
[TBL] [Abstract][Full Text] [Related]
9. Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery.
Remes K; Matinlauri I; Grenman S; Itälä M; Kauppila M; Pelliniemi TT; Salminen E; Vanharanta R; Rajamäki A
J Hematother; 1997 Feb; 6(1):13-9. PubMed ID: 9112214
[TBL] [Abstract][Full Text] [Related]
10. Combined positive and negative cell selection from allogeneic peripheral blood progenitor cells (PBPC) by use of immunomagnetic methods.
Martín-Henao GA; Picón M; Amill B; Querol S; Ferrà C; Grañena A; García J
Bone Marrow Transplant; 2001 Apr; 27(7):683-7. PubMed ID: 11360106
[TBL] [Abstract][Full Text] [Related]
11. Impact of leukapheresis cell composition on immunomagnetic cell selection with the Baxter Isolex 300i device: a statistical analysis.
Perotti C; Del Fante C; Viarengo GL; Bergamaschi P; Tinelli C; Bellotti L; Marchesi A; Parisi C; Salvaneschi L
Stem Cells Dev; 2004 Aug; 13(4):350-6. PubMed ID: 15345128
[TBL] [Abstract][Full Text] [Related]
12. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen.
Dawson MA; Schwarer AP; Muirhead JL; Bailey MJ; Bollard GM; Spencer A
Bone Marrow Transplant; 2005 Sep; 36(5):389-96. PubMed ID: 15980882
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of peripheral blood stem cell mobilization using G-CSF alone from healthy donors and patients with hematologic malignancies.
Kawamura K; Kikuchi M; Terasako K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Kimura S; Nakasone H; Okuda S; Yamazaki R; Kanda J; Kako S; Tanaka Y; Tanihara A; Nishida J; Kanda Y
Transfus Apher Sci; 2013 Oct; 49(2):334-40. PubMed ID: 23810219
[TBL] [Abstract][Full Text] [Related]
15. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
[TBL] [Abstract][Full Text] [Related]
16. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
17. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
[TBL] [Abstract][Full Text] [Related]
18. Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens.
Vogel W; Kopp HG; Kanz L; Einsele H
J Cancer Res Clin Oncol; 2002 Jul; 128(7):380-4. PubMed ID: 12136252
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of cure-oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomagnetic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group.
Ogura M; Kagami Y; Suzuki R; Miura K; Uehira K; Kurokawa T; Ito T; Kinoshita T; Emi N; Morishima Y; Kodera Y; Ueda R
Cancer Chemother Pharmacol; 1997; 40 Suppl():S51-7. PubMed ID: 9272135
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
